Results 51 to 60 of about 16,555,945 (165)

Bilateral vision loss as the initial presentation for central nervous system involvement of mantle cell lymphoma: A case series

American Journal of Ophthalmology Case Reports, 2021
Purpose: Mantle cell lymphoma is a rare aggressive subtype of non-Hodgkins B cell lymphoma. It typically presents with asymptomatic monoclonal lymphocytosis, lymphadenopathy or bulky extranodal disease.
L. Small, C. Ma, M. Shah, S. Ramanathan, N. Rasool   +4 more
doaj   +1 more source

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. [PDF]

PLoS ONE, 2017
Molecular alterations leading progression of asymptomatic CLL-like high-count monoclonal B lymphocytosis (hiMBL) to chronic lymphocytic leukemia (CLL) remain poorly understood.
María García-Álvarez, Miguel Alcoceba, Miriam López-Parra, Noemí Puig, Alicia Antón, Ana Balanzategui, Isabel Prieto-Conde, Cristina Jiménez, María E Sarasquete, M Carmen Chillón, María Laura Gutiérrez, Rocío Corral, José María Alonso, José Antonio Queizán, Julia Vidán, Emilia Pardal, María Jesús Peñarrubia, José M Bastida, Ramón García-Sanz, Luis Marín, Marcos González   +20 more
doaj   +1 more source

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

British Journal of Haematology, EarlyView.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.
Temitope Erinfolami, Amelia Fisher, Indrani Karpha, Yeong Lim, Nurunnahar Akter, Toyyib Abdulkareem, Brogan Johnston, Catrin Tudur Smith, Hilary Lindsay, Shaun Bowden, Debbie Yates, Lelia Duley, Renata Walewska, Stella Williams, David Allsup, Nagesh Kalakonda, Mark Bishton, Andrew Pettitt, Nicolas Martinez‐Calle   +18 more
wiley   +1 more source

Immune cell kinetics and antibody response in COVID‐19 patients with low‐count monoclonal B‐cell lymphocytosis

American journal of hematology/oncology, 2023
Low‐count monoclonal B‐cell lymphocytosis (MBLlo) has been associated with an underlying immunodeficiency and has recently emerged as a new risk factor for severe COVID‐19. Here, we investigated the kinetics of immune cell and antibody responses in blood
Guillermo Oliva-Ariza, Blanca Fuentes-Herrero, Q. Lécrevisse, C. Carbonell, Alba Pérez-Pons, Alba Torres-Valle, Julio Pozo, J. Martin-Oterino, Óscar González-López, Amparo López‐Bernús, Marta Bernal-Ribes, M. Belhassen-García, Oihane Pérez-Escurza, M. Pérez‐Andrés, Lourdes Vázquez, Guillermo Hernández-Pérez, Francisco Javier García Palomo, P. Leoz, Pilar Costa-Alba, Elena Pérez-Losada, Ana Yeguas, Miryam Santos Sánchez, M. García-Blázquez, F. Javier Morán-Plata, Daniela Damasceno, Vitor Botafogo, Noemí Muñoz-García, R. Fluxa, J. V. van Dongen, M. Marcos, Julia Almeida, A. Orfao   +31 more
semanticscholar   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source

ICSH Guidance on Bone Marrow Examination and Reporting

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber, Alexandar Tzankov, Olga Pozdnyakova, Hiromichi Matsushita, Gina Zini, Leonie Saft, on behalf of the International Council for Standardization in Haematology   +6 more
wiley   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases

MedComm, Volume 7, Issue 10, October 2026.
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley   +1 more source

Incidence, risk factors and outcomes of patients with monoclonal B cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism.

Journal of Thrombosis and Haemostasis
BACKGROUND The incidence, risk factors, and outcomes of venous thromboembolism (VTE) in patients with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL) is not well described.
A. Koehler, K. Rabe, D. Crusan, T. Call, S. Achenbach, P. Hampel, S. Kenderian, J. Leis, Yu-Cai Wang, Eli Muchtar, M. Tsang, T. Hilal, Ricardo D. Parrondo, Kent R. Bailey, W. Ding, Rachel J Bailen, S. Schwager, Min Shi, C. Hanson, S. Slager, Neil E. Kay, A. Ashrani, S. Parikh   +22 more
semanticscholar   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, Volume 117, Issue 4, Page 750-766, October 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source